Status:
RECRUITING
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Lead Sponsor:
Sohag University
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
35-65 years
Phase:
EARLY_PHASE1
Brief Summary
Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR . Retinal oedema is r...
Eligibility Criteria
Inclusion
- patients with type II DM and center involving DME with central foveal thickness more than 280 um.
Exclusion
- Evidence of macular ischemia
- Evidence of macular traction
- Previous intravitreal injections
- Previous macular laser therapy
- Previous pars plana vitrectomy
Key Trial Info
Start Date :
December 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 14 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06205979
Start Date
December 12 2023
End Date
June 14 2024
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag university Hospital
Sohag, Egypt